Cervical Screening

Information for Doctors

  • In 2017 the cytology-based Pap test was completely replaced by the Cervical Screening Test (CST).
  • The CST will be the only Medicare-funded routine cervical screening test, and will be available to women aged 25 and over.
  • Specimens need to be collected by clinicians into ThinPrep® vials.
  • Request forms must specify the requested test PLUS the reason for test PLUS supporting clinical notes.

A risk-based approach

The CST uses an HPV DNA test to detect the presence of oncogenic HPV types known to be associated with a higher risk of developing significant cervical abnormalities. The HPV test is more sensitive than cytology, so it can be performed less frequently.

  • Asymptomatic women who test negative for oncogenic HPV are at low risk of developing cervical cancer and only need to be screened every 5 years.
  • Asymptomatic women who test positive for oncogenic HPV will have a liquid-based cytology (LBC) test performed on the same sample (reflex LBC) and will be assessed as either intermediate risk and advised to return for further testing in 12 months, or higher risk and referred for colposcopy.
  • Symptomatic women and those with a history of high-grade cervical pathology will have both an HPV and LBC test (Co-test) performed, regardless of their HPV result.
  • Women with special circumstances identified by the program may be offered more frequent screening or a single screening test prior to age 25.


Available resources

Download Flyer - 'Self-collected HPV test' brochure

Self-collected HPV test - Sonic update January 2019

Contact us

For further information on the program, please contact GynaePath on (02) 9855 6200.